Management of Amphetamine and Methamphetamine Use Disorders: A Systematic Review and Network Meta-analysis of Randomized Trials.
The current evidence regarding effective management of methamphetamine and amphetamine (MA/A) use disorders is inconclusive. Therefore, we assessed the comparative benefits and tolerability of pharmacological, psychosocial, and harm reduction interventions for management of MA/A use disorders. We se...
| Publicado en: | International Journal of Mental Health & Addiction Vol. 23; no. 6; pp. 4768 - 4787 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | Literature Review |
| Publicado: |
Springer Nature
Dec2025
|
| Materias: | |
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ssf&AN=190202164&site=ehost-live header: @attributes: shortDbName: ssf uiTerm: 190202164 longDbName: Social Sciences Full Text (H.W. Wilson) uiTag: AN controlInfo: bkinfo: jinfo: jid: 15571874 46AW jtl: International Journal of Mental Health & Addiction issn: 15571874 maglogo: N pubinfo: dt: Dec2025 vid: 23 iid: 6 pid: 237 pub: Springer Nature artinfo: ui: 190202164 10.1007/s11469-024-01379-w ppf: 4768 ppct: 19 formats: fmt: – @attributes: type: T – @attributes: type: P size: 1.3MB tig: atl: Management of Amphetamine and Methamphetamine Use Disorders: A Systematic Review and Network Meta-analysis of Randomized Trials. aug: au: Khalili, Malahat Sadeghirad, Behnam Bach, Paxton Crabtree, Alexis Javadi, Sara Sadeghi, Erfan Moradi, Sara Mirzayeh Fashami, Fatemeh Nakhaeizadeh, Mehran Salehi, Sahar Sofi-Mahmudi, Ahmad Nasiri, Naser Mehmandoost, Soheil Moallef, Soroush Langeroodi, Shahryar Moradi Falah Moe, Jessica Lysyshyn, Mark Werb, Dan Buxton, Jane A. Karamouzian, Mohammad affil: https://ror.org/02fa3aq29 Michael G. DeGroote Institute for Pain Research and Care, McMaster University, Hamilton, ON, Canada https://ror.org/02fa3aq29 Department of Anesthesia, McMaster University, Hamilton, ON, Canada https://ror.org/02fa3aq29 Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada https://ror.org/03rmrcq20 Department of Medicine, University of British Columbia, Vancouver, BC, Canada https://ror.org/00wzdr059 British Columbia Centre On Substance Use, St Paul's Hospital, Vancouver, BC, Canada https://ror.org/05jyzx602 British Columbia Centre for Disease Control, Vancouver, BC, Canada https://ror.org/03rmrcq20 School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada https://ror.org/01n3s4692 Vice Chancellor for Research Technology, Shiraz University of Medical Sciences, Shiraz, Iran https://ror.org/01n3s4692 Department of Biostatistics, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran https://ror.org/02kxbqc24 Modeling in Health Research Center, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran https://ror.org/02kxbqc24 Department of Biostatistics and Epidemiology, Faculty of Public Health, Kerman University of Medical Sciences, Kerman, Iran School of Public Health, Jiroft University of Medical Sciences, Jiroft, Kerman, Iran https://ror.org/02kxbqc24 HIV/STI Surveillance Research Center, and WHO Collaborating Center for HIV Surveillance, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran https://ror.org/03vek6s52 T.H. Chan School of Public Health, Harvard University, Boston, MA, USA https://ror.org/03rmrcq20 Department of Emergency Medicine, University of British Columbia, Vancouver, BC, Canada https://ror.org/03bd8jh67 Vancouver Coastal Health, Vancouver, BC, Canada https://ror.org/04skqfp25 Centre On Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada https://ror.org/0168r3w48 Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, San Diego, CA, USA https://ror.org/03dbr7087 Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada su: Clinical trials Medical care research Substance-induced disorders Psychotherapy Methamphetamine Amphetamines Drug therapy Critical analysis sug: subj: Clinical trials Medical care research Substance-induced disorders Psychotherapy Pharmaceutical and medicine manufacturing Medicinal and Botanical Manufacturing Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) Methamphetamine Amphetamines Drug therapy Critical analysis keyword: Amphetamine-related disorders Medical and Health Sciences Clinical Sciences Methamphetamine use disorder Network meta-analysis Systematic review Amphetamine-related disorders Medical and Health Sciences Clinical Sciences Methamphetamine use disorder Network meta-analysis Systematic review ab: The current evidence regarding effective management of methamphetamine and amphetamine (MA/A) use disorders is inconclusive. Therefore, we assessed the comparative benefits and tolerability of pharmacological, psychosocial, and harm reduction interventions for management of MA/A use disorders. We searched six electronic databases for randomized controlled trials of any pharmacological, psychosocial, or harm reduction interventions in adults with MA/A use disorders. We performed a random-effects frequentist network meta-analysis and used the GRADE approach to assess the certainty of evidence. We included 72 randomized trials (6836 participants). Low certainty evidence suggests quetiapine may extend abstinence compared to placebo [risk ratio (RR) 3.17 (95% confidence intervals (CI), 1.24 to 8.07)] and weekly average proportion of patients with negative urine samples [mean difference (MD) 32.17 (95% CI, 14.08 to 50.26)]. Low certainty evidence also suggested that riluzole may be associated with a higher weekly average proportion of patients with negative urine samples [MD 24.10 (95% CI, 5.54 to 42.66)]. Very low certainty evidence suggests methylphenidate alone [compared to placebo MD 10.24 (95% CI, 3.49 to 16.99)] or in combination with matrix model [MD 23.55 (95% CI, 7.64 to 39.46)] may be associated with an increased weekly average proportion of patients with negative urine samples. Compared to placebo, contingency management alone [MD 21.20 (95% CI, 11.39 to 31.00), very low certainty] or in combination with cognitive behavioural therapy [MD 34.85 (95% CI, 19.63 to 50.08), very low certainty] may be associated with longer duration of abstinence. Compared to placebo, venlafaxine [RR 0.27 (95% CI 0.08 to 0.90), low certainty] and citicoline [RR 0.69 (95% CI 0.49 to 0.99), lowcertainty] may be among the most tolerable interventions. Very few interventions may be associated with slight improvement in certain outcomes, but no intervention showed moderate- to high-certainty evidence for important changes across any patient-important outcomes. pubtype: Academic Journal doctype: Literature Review src: R language: English refInfo: copyright: @attributes: flag: N holdings: @attributes: islocal: N |
|---|